Citius Pharmaceuticals, Inc. (CTXR) vs Karyopharm Therapeutics Inc. (KPTI)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.51HealthcareDelayed quote: Oct 6, 2026, 10:43 AM EDT
KPTI
Karyopharm Therapeutics Inc.
$0.64HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
Total return — CTXR vs KPTI
growth of $100 · dividends reinvested · last 10yCTXR -99.8% (-46.2%/yr)KPTI -99.5% (-41.7%/yr)KPTI compounded faster over this window
CTXR KPTI
CTXR vs KPTI: by the numbers
- •KPTI is the larger company ($14M vs $14M market cap).
- •Both run net losses; KPTI's is the smaller (-153.28% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CTXR | KPTI |
|---|---|---|
| P/S ratio | 1.97 | 0.10 |
| P/B ratio | 0.21 | N/A |
Profitability
| Metric | CTXR | KPTI |
|---|---|---|
| Gross margin | 0.00% | 95.88% |
| Operating margin | 0.00% | -56.17% |
| Net margin | -651.27% | -153.28% |
| ROE | -69.47% | N/A |
| ROIC | -67.62% | N/A |
Growth (annualized)
| Metric | CTXR | KPTI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.47% |
| Total return CAGR (5Y) | -60.04% | -62.18% |
Frequently asked
- How have CTXR and KPTI total returns compared?
- Over the past 10 years, CTXR delivered -46.34% and KPTI delivered -41.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.